EXINI has entered into a collaboration with the PCCTC to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer. The PCCTC is a premier multicenter clinical research organization specializing in cutting-edge prostate cancer research recognized for its culture of transparent project co-development between investigators, research sites and industry partners. The intent of the strategic collaboration is to integrate the AI platform into early phase PCCTC studies to advance the discovery, development and validation of novel AI-enabled biomarkers. 
Read More!